Flexibility | VELPHORO® (sucroferric oxyhydroxide)

Uniquely Velphoro: Flexible administration options add to patient convenience and control1

Easy to break or crush, easy to chew, easy starting dose
Easy to break or crush, easy to chew, easy starting dose
Easy to break or crush, easy to chew, easy starting dose

Uniquely Velphoro: Data show giving patients choices
improved acceptance†3

When given a choice to chew Velphoro or break and swallow†3:

Nearly 

8 out of 10

 patients accepted Velphoro

 

Velphoro Check Mark and Thumbs Up
Velphoro Check Mark and Thumbs Up
Velphoro Check Mark and Thumbs Up

89%

of patients chose to break and swallow instead of chew

Velphoro Broken Pill and Throat illustration
Velphoro Broken Pill and Throat illustration
Velphoro Broken Pill and Throat illustration

Velphoro dosing is simple for patients, easy for
healthcare providers1

Recommended starting dose

Picture of 3 pills
Picture of 3 pills
Picture of 3 pills

1 tablet per meal
=
3 tablets per day1

Titrate by 1 tablet per day, as required 

Picture of 1 pill
Picture of 1 pill
Picture of 1 pill

Increase by 1 tablet per day
(not per meal) 
until serum phosphorus 
levels are under control, 
as often as weekly1

Maintain phosphorus control 

Picture of 4 pills
Picture of 4 pills
Picture of 4 pills

Most patients required
3-4 tablets per day,
HALF the pills
vs some other binders1,4

High adherence demonstrated in clinical and real-world settings4,5

Bar graph of high adherence demonstrate in clinical and real-world settings
Bar graph of high adherence demonstrate in clinical and real-world settings
Bar graph of high adherence demonstrate in clinical and real-world settings

*Presenter is a paid speaker and has been compensated for their time.

Prospective analysis of 105 patients on hemodialysis to assess acceptance and strategies that support compliance in clinical practice. All patients were on a phosphate binder: at baseline, 57 were switched to Velphoro and 48 maintained their baseline treatment. Patients were informed about various modes of administration and were permitted to adapt administration based on preference.3

A 52-week, open-label, active-controlled, phase 3 study evaluated the safety and efficacy of Velphoro in lowering serum phosphorus levels in patients (N=1,054) with chronic kidney disease on hemodialysis or peritoneal dialysis. In the titration phase (first 24 weeks), patients were randomized to receive either Velphoro or sevelamer carbonate to establish the noninferiority of Velphoro to sevelamer carbonate in lowering serum phosphorus at 12 weeks (secondary endpoint). The following withdrawal phase (weeks 24 to 27, n=93) established the superiority of Velphoro with an effective maintenance dose over a placebo-like low dose (primary endpoint). During a final long-term maintenance phase (weeks 28 to 52, n=658), patients continued phosphate binder treatment according to their original randomization for the assessment of long-term efficacy, safety, and tolerability.1

§A retrospective analysis of deidentified pharmacy data from adult hemodialysis patients (n=490) who were enrolled with the DaVita pharmacy service for at least 6 months. Subjects were patients who converted to Velphoro monotherapy from another phosphate binder during routine care between April 2014 and September 2016. The decision to switch phosphate binders (PBs) was made on a clinical basis and the reasons underlying this change were not available. Primary outcomes were total daily PB pill burden, total PB medication possession ratio, serum phosphorus, and percentage of patients with serum phosphorus ≤5.5 mg/dL.5

References: 1. Velphoro® [package insert]. Waltham, MA: Fresenius Medical Care North America: 2020. 2. Lanz M, Baldischweiler J, Kriwet B, Schill J, Stafford J, Imanidis G. Chewability testing in the development of a chewable tablet for hyperphosphatemia. Drug Dev Ind Pharm. 2014;40(12):1623-1631. 3. Arenas Jiménez MD, Navarro González JF. How to improve adherence the captors of phosphorus on hemodialysis: experience in real life with sucroferric oxyhydroxide. Nefrologia (Engl Ed). 2020;40(6):640-646. 4. Floege J, Covic AC, Ketteler M, et al; on behalf of the Sucroferric Oxyhydroxide Study Group. Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients. Nephrol Dial Transplant. 2015;30(6):1037-1046. 5. Gray K, Ficociello LH, Hunt AE, Mullon C, Brunelli SM. Phosphate binder pill burden, adherence, and serum phosphorus control among hemodialysis patients converting to sucroferric oxyhydroxide. Int J Nephrol Renovasc Dis. 2019;12:1-8. 6. Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117-122.